Trending Stories

Insights and updates

Ascletis’ Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight USA – English APAC – Traditional Chinese APAC – English

[ad_1] –  ASC30 once-daily tablets showed statistically significant and clinically meaningful dose-dependent placebo-adjusted mean body weight reductions with no observed plateau for weight loss. –  ASC30 titrated weekly to target dose demonstrated approximately one-half the […]